AffaMed Therapeutics Successfully Hosts DEXTENZA Launch and Expert Symposium in Macao

ShanghaiMay 10, 2022PR Newswire -- AffaMed Therapeutics, a clinical-stage biopharmaceutical company dedicated to addressing global unmet medical needs in ophthalmology, neurology, and psychiatry, recently hosted the launch event and professional symposium for DEXTENZA in Macao following the official approval of DEXTENZA by Macao's health authorities for treating ocular pain and inflammation after ophthalmic surgery. Director Yifan Lai from Kiang Wu Hospital in Macao and the Harvard Ophthalmology Association participated in the event.John HovanesianPh.D., Columbus Eye CenterAlice EpitropoulosPh.D., and 21 doctors from multiple hospitals and institutions in Macao and Hong Kong attended the meeting either in person or online.

This meeting aims to promote academic and clinical exchanges, share the benefits that DEXTENZA can bring to patients, and consult with doctors from Macao and Hong Kong on their insights into the treatment of postoperative ocular pain and inflammation. The themes of the meeting include "Clinical Application of Corticosteroids in Macao and Unmet Clinical Needs," "Introduction to the Clinical Benefits of DEXTENZA," "Sharing of Clinical Experience with DEXTENZA," and academic discussions.

Dr. Dayao Zhao, CEO of AffaMed Therapeutics, attended the conference online and stated: "DEXTENZA has made significant progress in the pilot zones on Mainland China and in Macao. We are delighted that this excellent product has been launched in Macao, and we look forward to collaborating with experts to provide a preservative-free and non-invasive treatment option for patients suffering from ocular pain and inflammation after ophthalmic surgery in Macao."

Dr. Lai Yifan, Director of Kiang Wu Hospital in Macau, said: "The launch of DEXTENZA in Macau is exciting news for us. Its innovative hydrogel technology will help reduce drug side effects and improve the treatment experience and convenience. The two American experts shared very valuable experiences, helping us fully understand the current clinical application of DEXTENZA."

Dr. John Hovanesian of the Harvard Ophthalmology Association stated, "We are delighted to join our peers in Macao for the launch of this innovative technology. Continuous drug delivery offers significant convenience to patients, and with a proven safety platform, surgeons' clinical confidence has also been enhanced."

Dr. Alice Epitropoulos from the Columbus Eye Center stated, "DEXTENZA improves patient compliance and promotes healthier ocular surfaces, making it a significant advancement in steroid treatment. I am truly delighted that this innovative drug delivery technology has been introduced in Macao, benefiting both surgeons and patients there."

In 2020, AffaMed Therapeutics entered into an exclusive license agreement with Ocular Therapeutix (NASDAQ: OCUL) to gain the rights to develop and commercialize DEXTENZA in Greater China, South Korea, and ASEAN markets. Currently, DEXTENZA has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of ocular inflammation and pain following ophthalmic surgery, as well as eye itching associated with allergic conjunctivitis.